Specificity and mechanism of action of some commonly used protein kinase inhibitors

Biochemical Journal

Volumn 351, Issue 1, 2000, Pages 95-105

  Davies, S P ^a   Reddy, H ^a   Caivano, M ^a   Cohen, P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

PD 184352; PD 98059; Protein phosphorylation; SB 203580; U0126

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [2 METHYL 5 [4 (4 METHYL 1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (3 ETHYNYLANILINO) 6,7 BIS(2 METHOXYETHOXY)QUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BISINDOLYLMALEIMIDE; CASEIN KINASE II; FASUDIL; K 252C; KT 5720; LEFLUNOMIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PD 173074; PD 184352; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; QUERCETIN; RAPAMYCIN; RO 31 8220; ROTTLERIN; U 0126; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ACETOPHENONES; AMIDES; ANIMAL; BENZAMIDES; BENZOPYRANS; BUTADIENES; CELL LINE; ENZYME INHIBITORS; FLAVONES; HUMAN; IMIDAZOLES; INDOLES; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; LITHIUM; MAGNESIUM; NITRILES; PHENANTHRIDINES; PHOSPHORYLATION; POTASSIUM CHLORIDE; PROTEIN KINASES; PYRIDINES; SIROLIMUS; SUBSTRATE SPECIFICITY; SUPPORT, NON-U.S. GOV'T;

EID: 0034306450     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/0264-6021:3510095     Document Type: Article

References (56)

1. The development and therapeutic potential of protein kinase inhibitors
2. TOR signalling and control of cell growth
3. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)- phenyl]5-methylisoxazole-4-carboxamide
4. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
5. EGF receptor tyrosine kinase inhibitors as anti-cancer agents: Pre-clinical and early clinical profile of ZD 1839
6. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
7. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
8. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
9. The search for physiological substrates of MAP and SAP kinases in mammalian cells
10. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stress and interleukin-1
11. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution
12. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket
13. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function
14. PD 98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
15. A synthetic inhibitor of the mitogen-activated protein kinase cascade
16. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
17. Gβγ stimulates phosphoinositide 3-kinase-γ by direct interaction with two domains of the catalytic p110 subunit
18. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
19. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase)
20. Transformation mediated by RhoA requires activity of ROCK kinases
21. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells
22. Rho-kinase in human neutrophils: A role in signalling for myosin light chain phosphorylation and cell migration
23. The COOH terminus of Rho-kinase negatively regulates Rho-kinase activity
24. A protein kinase inhibitor, fusudil (AT-877): A novel approach to signal transduction therapy
25. Infra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage
26. Rottlerin, a novel protein kinase inhibitor
27. 2+/calmodulin-dependent protein kinase II
28. Molecular and cellular pharmacology of a calcium/calmodulin-dependent protein kinase II (CaM kinase II) inhibitor, KN62, and proposal of CaM kinase phosphorylation cascades
29. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
30. Inhibition of mitogen-activated protein kinase blocks T cell proliferation but does not induce or prevent anergy
31. Wortmannin, a microbial product inhibitor of myosin light chain kinase
32. Lithium inhibits glycogen synthase kinase-3 activity and mimics Wingless signalling in intact cells
33. 'Insulin-like' effects of lithium ion on isolated rat adipocytes. II. Specific activation of glycogen synthase
34. Multisite phosphorylation of glycogen synthase from rabbit skeletal muscle. Phosphorylation of site 5 by glycogen synthase kinase-5 (casein kinase-II) is a prerequisite for phosphorylation of sites 3 by glycogen synthase kinase-3
35. Potent selective inhibitors of protein kinase C
36. The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1β (Rsk-2) and p70 S6 kinase
37. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB
38. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203X) and IX (Ro-31-8220) are potent inhibitors of glycogen synthase kinase-3 activity
39. Inhibition of voltage-dependent sodium channels by Ro 31-8220, a 'specific' protein kinase C inhibitor
40. UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase
41. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
42. The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase
43. Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3
44. Role of mitogen-activated protein kinase cascades in mediating lipopolysaccharide-stimulated induction of cyclooxygenase-2 and IL-1β in RAW264 macrophages
45. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus
46. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase
47. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding
48. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
49. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
50. Paradoxical activation of Raf by a novel Raf inhibitor
51. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T ceils independently of p38 mitogen-activated protein kinase
52. 2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-activated protein kinase-activated protein kinase-2
53. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580
54. Control of p70 S6 kinase by kinase activity of FRAP in vivo
55. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo
56. Inactivation of glycogen synthase kinase 3β by phosphorylation: New kinase connections in insulin and growth-factor signalling